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INTRODUCTION 
1.1. MICROSPHERES AS CONTROLLED DRUG DELIVERY SYSTEM 
                   For many decades, medications of an acute disease or a chronic illness has been 
accomplished by delivering drugs to the patients via various pharmaceutical dosage forms like 
tablets, capsules, pills, creams, ointments, liquids, aerosols, injectables and suppositories  as 
carriers. To achieve and then to maintain the concentration of drug administered within the 
therapeutically effective range needed for medication, it is often necessary to take this type of 
drug delivery systems several times a day. This results in a fluctuated drug level and 
consequently undesirable toxicity and poor efficiency. 
                  This factor as well as other factors such as repetitive dosing and predictable 
absorption leads to the concept of controlled drug delivery systems.1, 2. 
                  The objectives of controlled release drug delivery include two important aspects 
namely spatial arrangement and temporal delivery of drug. 
                   Spatial placement relates to targeting a drug to a specific organ or tissue, while 
temporal delivery refers to controlling the rate of drug delivery to the target tissue. 
                   An approximately designed controlled release drug delivery system can be a major 
advance towards solving these two problems. It is this reason that the science and technology 
responsible for development of controlled release pharmaceuticals have been and continue to be 
the focus of a great deal of attention both industrial and academic laboratories. 
                   A controlled release system includes any drug delivery system that “achieves slow 
release of the drug over an extended period of time”. If the system can provide some control 
weather this of a temporal or a spatial nature, in other words, if the system is successful in 
maintaining predictable and reproducible kinetics in the target tissue or cell, it is considered as a 
controlled release system.  
                   If the system only extends the duration of release without reproducible kinetics it is 
considered as a prolong release system. 
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                  The objectives in designing a controlled release system are to deliver the drug at a 
rate necessary to achieve and maintain a constant drug blood level. This rate should be analogous 
to that achieved by continuous intravenous infusion where a drug is provided to the patient at a 
rate just equal to its rate of elimination. This complies that the rate of delivery must be 
independent of the amount of drug remaining in the dosage form and constant over time. That is 
release from the dosage form should follow zero-order kinetics3.  
                  The several advantages of a controlled drug delivery system over a conventional 
dosage forms: 
• Improved patient convenience and compliance due to less frequent drug administration. 
• Reduction in fluctuation in steady state levels and therefore better control of disease 
condition and reduced intensity of local or systemic side effects. 
• Increased safety margin of high potency drugs due to better control of plasma levels. 
• Maximum utilization of drug enabling reduction in total amount of dose administered. 
• Reduction in health care costs through improved therapy, shorter treatment period, less 
frequency of dosing and reduction in personnel time to dispense, administer and monitor 
patients4. 
 
 1.2. LISINOPRIL DI HYDRATE 
                  Lisinopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE) 
and is used to treat high blood pressure (hypertension), heart failure and to improve survival after 
heart attack. Lisinopril, one of the few ACE inhibitors that is not a pro-drug, compete with ATI 
for binding to ACE and inhibits and enzymatic proteolysis of AT-I to AT-II. Lisinopril, a 
synthetic peptide derivative, is chemically described as (S)-1-[N2-(1-carboxy-3- phenylpropyl)-
L-lysyl]-L-proline dihydrate5. Lisinopril inhibits angiotensin-converting enzyme (ACE) in 
human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of 
angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates 
aldosterone secretion by the adrenal cortex.  
                 The beneficial effects of Lisinopril in hypertension and heart failure appear to result 
primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE 
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results in decreased plasma angiotensin II which leads to decreased vasopressor activity and to 
decrease aldosterone secretion. The latter decrease may result in a small increase of serum 
potassium. In hypertensive patients with normal renal function treated with Lisinopril alone for 
up to 24 weeks, the mean increase in serum potassium was approximately 0.1mEq/L however, 
approximately 15% of patients had increases greater than 0.5mEq/L and approximately 6% had a 
decrease greater than 0.5mEq/L. In the same study, patients treated with Lisinopril and 
hydrochlorothiazide for up to 24 weeks had a mean decrease in serum potassium of 0.1mEq/L; 
approximately 4% of patients had increases greater than 0.5 mEq/L and approximately 12% had 
a decrease greater than 0.5mEq/L. 
                Concomitant administration of Lisinopril and hydrochlorothiazide further reduced 
blood pressure in Black and non-Black patients and any racial differences in blood pressure 
response were no longer evident. Administration of Lisinopril to patients with hypertension 
results in a reduction of both supine and standing blood pressure to about the same extent with 
no compensatory tachycardia. Symptomatic postural hypotension is usually not observed 
although it can occur and should be anticipated in volume and/or salt-depleted patients. In most 
patients studied, onset of antihypertensive activity was seen at one hour after oral administration 
of an individual dose of Lisinopril, with peak reduction of blood pressure achieved by 6 hours. 
Although an antihypertensive effect was observed 24 hours after dosing with recommended 
single daily doses, the effect was more consistent and the mean effect was considerably larger in 
some studies with doses of 20 mg or more than with lower doses; however, at all doses studied, 
the mean antihypertensive effect was substantially smaller 24 hours after dosing than it was 6 
hours after dosing. In some patients achievement of optimal blood pressure reduction may 
require two to four weeks of therapy. 
    Upon multiple dosing, Lisinopril exhibits an effective half-life of accumulation of 12 
hours. Impaired renal function decreases elimination of Lisinopril, which is excreted principally 
through the kidneys, but this decrease becomes clinically important only when the glomerular 
filtration rate is below 30mL/min. 
              Lisinopril 20 mg to 80 mg has been compared in patients with mild to moderate 
hypertension to hydrochlorothiazide 12.5 mg to 50 mg and with atenolol 50 mg to 200 mg; and 
in patients with moderate to severe hypertension to Metoprolol 100 mg to 200 mg. It was 
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superior to hydrochlorothiazide in effects on systolic and diastolic pressure in a population that 
was 3/4 Caucasian. Lisinopril was approximately equivalent to Atenolol and Metoprolol in 
effects on diastolic blood pressure, and had somewhat greater effects on systolic blood pressure.  
    In patients with renovascular hypertension Lisinopril has been shown to be well 
tolerated and effective in controlling blood pressure. 
1.3 Microencapsulation 
             Microencapsulation is a process by which very tiny droplets or particles of liquid or solid 
material are surrounded or coated with a continuous film of polymeric material. In 
microencapsulation particle size is ranging from several tenths to 5000 microns6.  
             Microencapsulation provides the means of converting liquids to solids, of altering 
colloidal and surface properties, of providing environmental protection and of controlling the 
release characteristics or availability of coated materials. Several of these properties can be 
attained by macro packaging techniques; however, the uniqueness of microencapsulation is the 
smallness of the coated particles and their subsequent use and adaptation to a wide variety of 
dosage forms7. 
REASONS FOR MICROENCAPSULATION8 
 The primary reason for microencapsulation is found to be either for sustained or 
prolonged drug release. 
 This technique has been widely used for masking taste and odor of many drugs to 
improve patient compliance. 
 This technique can be used for converting liquid drugs in a free flowing powder. 
 The drugs, which are sensitive to oxygen, moisture or light, can be stabilized by 
microencapsulation. 
 Incompatibility among the drugs can be prevented by microencapsulation. 
 Vaporization of many volatile drugs e.g. methyl salicylate and peppermint oil can be 
prevented by microencapsulation. 
 Many drugs have been microencapsulated to reduce toxicity and GI irritation including 
ferrous sulphate and KCl. 
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 Alteration in site of absorption can also be achieved by microencapsulation. 
 Toxic chemicals such as insecticides may be microencapsulated to reduce the possibility 
of sensitization of factorial person. 
 Bakan and Anderson reported that microencapsulated vitamin A palmitate had enhanced 
stability8.  
RELEASE MECHANISMS8 
Mechanisms of drug release from microspheres are 
1. Degradation controlled monolithic system: - 
The drug is dissolved in matrix and is distributed uniformly throughout. The drug is 
strongly attached to the matrix and is released on degradation of the matrix. The diffusion of the 
drug is slow as compared with degradation of the matrix. 
2. Diffusion controlled monolithic system: - 
Here the active agent is released by diffusion prior to or concurrent with the degradation 
of the polymer matrix. Rate of release also depend upon where the polymer degrades by 
homogeneous or heterogeneous mechanism. 
3. Diffusion controlled reservoir system: - 
Here the active agent is encapsulated by a rate controlling membrane through which the 
agent diffuses and the membrane erodes only after its delivery is completed. In this case, drug 
release is unaffected by the degradation of the matrix. 
4. Erosion: - 
Erosion of the coat due to pH and enzymatic hydrolysis causes drug release with certain 
coat material like glyceryl mono stearate, beeswax and steryl alcohol etc. 
 
METHODS TO MANUFACTURE MICROSPHERES9 
  Basic Microencapsulation processes can be divided into  
              Chemical methods 
              Physico-chemical methods 
              Mechanical methods 
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Chemical methods 
• Solvent Evaporation 
• Interfacial polymerization/cross linking 
• In-situ polymerization 
• Matrix polymerization 
• Polymer-polymer compatibility 
• In-liquid drying 
• Thermal and ionic gelation in liquid media 
Physico-chemical methods 
• Ionotropic gelation 
• Coacervation phase separation 
 
Mechanical methods 
• Pan coating 
• Air suspension coating 
• Centrifugal extrusion 
• Spray drying 
• Spray coating 
• Spinning disk or rotational suspension separation 
• Electrostatic deposition 
• Pressure extraction or spraying into solvent extraction bath11. 
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                                                                        Table No.1 
Microencapsulation Processes and Their Applicabilities 
 
S.No. Method name Applicable material Particle size 
(µm) 
1 Air suspension solids 35-5000 
2 Coacervatio-phase seperation Solids&liquids 2-5000 
3 Multi orifice centrifugal process Solids&liquids 1-5000 
4 Pan coating Solids 600-5000 
5 Solvent evaporation Solids&liquids 5-5000 
6 Spray drying and congealing Solids&liquids 600 
 
 
Ideal characteristics of drug for microencapsulation5 
Particle size requirement 
 The lower the molecular weight, faster and complete is the absorption of the drug. The 
drugs having size 150-600 Daltons they can easily diffuse through the membrane but diffusivity 
(the ability of drug to diffuse through the membrane) is inversely related to molecular size. 
The drug or protein should not be adversely affected by the process. 
Reproducibility of release profile and the method 
No stability problem 
  Drugs unstable in GI environment cannot be administered as oral controlled release 
formulation because of bioavailability problems. E.g.Nitroglycerine. 
There should be no toxic product associated with the final product. 
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Therapeutic range 
 A candidate drug for controlled delivery system should have a therapeutic range wide 
enough such that variations in the release rate do not result in a concentration beyond this level. 
Therapeutic index 
  The ratio of maximum safe concentration to the minimum effective concentration of drug 
is called as therapeutic index. The release rate of drug with narrow therapeutic index should be 
such that the plasma concentration is attained between the therapeutically safe and effective 
range. It is necessary because such drugs have toxic concentration nearer to their therapeutic 
range. 
 Elimination half life 
 Smaller the half life larger the amount of drug to be incorporated in the controlled 
release dosage form. Drugs with t1\2   in the range of 2-4 hours make a good candidates for such a 
system. E.g.propronalol. 
Plasma Concentration-Response relationship 
Drugs whose pharmacological activity is independent of its concentration are poor 
candidates for controlled release systems. 
Microencapsulation of pharmaceuticals is undertaken for the following 
applications9, 10: 
 Microencapsulation has been employed to provide protection to the core material against 
atmospheric effects. The separation of incompatible substances, for example pharmaceutical 
eutectics, has been achieved by encapsulation. Toxic chemicals such as insecticides may be 
microencapsulated to reduce hazards. Also the hygroscopic properties of many core materials 
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Microencapsulation by Coacervation Phase Separation Technique8 
Preparation 
The core material will be added to the solution. The core material should not react or 
dissolve in water (maximum solubility 2%) The core material is dispersed in the solution. The 
particle size will be defined by dispersion parameter, as stirring speed, stirrer shape, surface 
tension and viscosity. Size range 2µm - 1200µm 
Coacervation 
• Coacervation starts with a change of the pH value of the dispersion, e.g. by adding organic 
acids. The result is a reduction of the solubility of the dispersed phases (shell material). 
• The shell material (coacervate) starts to precipitate from the solution. 
• The shell material forms a continuous coating around the core droplets. 
Cooling and hardening phase 
• The shell material is cooled down to harden and forms the final capsule. 
• Hardening agents like formaldehyde can be added to the process. 
• The microcapsules are now stable in the suspension and ready to be dried. 
Drying phase 
• The suspension is dried in a spray dryer or in a fluidized bed drier. 
• Spray Drying is a suitable method for heat sensitive Products. 
• The atomized particles assume a spherical shape. The rapid the coating material keeps the core   
material below 100°C, even if the temperature in the drying chamber is much greater. 
• Microencapsulation makes the spray drying process easier for sticky products like fruit pulp or 
juice, with a high content of invert sugar. 
Coacervation-Phase Separation 
The general outline of the processes consists of three steps carried out under continuous 
agitation: 
1. Formation of three immiscible chemical phases – A liquid manufacturing vehicle phase, a core 
material phase, and a coating material phase. To form the three phases, the core material 
dispersed in a solution of the coating polymer, the solvent for the polymer being the liquid 
manufacturing vehicle phase. The coating 
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material phase, an immiscible polymer in a liquid state, is formed by utilizing one of the methods 
of the methods of phase separation-coacervation, i.e., by changing the temperature of the 
polymer solution; or by adding a salt, nonsolvent, or incompatible polymer to the polymer 
solution; or by inducing a polymerpolymer interaction. 
2. Deposition of the coating – It consists of depositing the liquid polymer coating upon the core 
material. This is accomplished by controlled, physical mixing of the material in the 
manufacturing vehicle. Deposition if the liquid polymer coating around the core material occurs 
if the polymer is adsorbed at the interface formed between the core material and the liquid 
vehicle phase, and this adsorption phenomenon is a prerequisite to effective coating. The 
continued deposition of the coating material is promoted by a reduction in the total free 
interfacial energy of the system, brought about by the decrease of the coating material surface 
area during coleasance of the liquid polymer droplets. 
3. Rigidization of the coating – It involves rigidizing the coating, usually by thermal, cross-
linking, or desolvation techniques, to form a self-sustaining microcapsules. 
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1.4. POLYMERS USED FOR MICROSPHERES12
 






Lactides and Glycolides copolymers 














Starch agarose  
Carrageenan  
Chitosan  
Chemically modified carbohydrates 
Poly (acryl) dextran  
Poly (acryl) starch 
             
CLASSIFICATION OF POLYMERS13 
Water-Soluble Synthetic Polymers 
• Poly (acrylic acid) cosmetic, pharmaceuticals, immobilization of Cationic drugs, base for 
Carbopol polymers. 
• Poly (ethylene oxide) Coagulant, flocculent, very high molecular-weight up to a few 
millions, swelling agent. 
• Poly (ethylene glycol) Mw <10,000; liquid (Mw <1000) and wax (Mw >1000), 
Plasticizer, base for suppositories. 
• Poly (vinyl pyrrolidone) used to make betadine (iodine complex of PVP) with less 
toxicity than iodine, plasma replacement and tablet granulation. 
• Poly (vinyl alcohol) Water-soluble packaging, tablet binder, tablet coating. 
• Polyacrylamide Gel electrophoresis to separate proteins based on their molecular 
weights, coagulant, absorbent. 
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• Poly (isopropyl acrylamide) and poly (cyclopropyl methacrylamide) are thermogelling 
acrylamide derivatives, its balance of hydrogen bonding, and hydrophobic association 
changes with temperature. 
 
 Cellulose-Based Polymers13 
• Ethyl cellulose is insoluble but dispersible in water, used in aqueous coating system for 
sustained release applications. 
• Carboxymethyl cellulose is super disintegrant and emulsion stabilizer. 
• Hydroxyethyl and hydroxypropyl celluloses are soluble in water and in alcohol, used in 
tablet coating. 
• Hydroxypropyl methyl cellulose is Binder for tablet matrix and tablet coating, gelatin 
alternative as capsule material. 
• Cellulose acetate phthalate generally used in Enteric coating. 
 
Hydrocolloids 
• Alginic acid is used in oral and topical pharmaceutical products; thickening and 
suspending agent in a variety of pastes, creams, and gels, as well as a stabilizing agent for 
oil-in-water emulsions; binder and disintegrant. 
• Gelatin a protein derivative and natural polymer used for controlled release of drug by 
using suitable cross linking agent. 
• Chitosan Cosmetics and controlled drug delivery applications, mucoadhesive dosage 
forms, rapid release dosage forms. 
 
Water-Insoluble Biodegradable Polymers13 
• (Lactide-co-glycolide) polymers Microparticle–nanoparticle for protein delivery. 
 
Starch-Based Polymers 
• Starch is used as Glidant, a diluent in tablets and capsules, a disintegrant in tablets and 
capsules, a tablet binder. 
• Sodium starch glycolate is super disintegrant for tablets and capsules in oral delivery. 
INTRODUCTION 
 
Padmavathi College of Pharmacy And Research Institute  14 
 
1.5. METHODS TO MANUFACTURE OF GELATIN LOADED 
MICROSPHERES8, 10 
                   Gelatin loaded microspheres can be prepared by using any one of the different 
following techniques 
 
Single Emulsion Polymerization Technique 
                    Single Emulsion Technique the micro particulate carriers of natural polymers, i.e. 
those of proteins (e.g. gelatin) and carbohydrates (sodium alginate, chitosan) are prepared by 
single emulsion technique. The natural polymers are dissolved or dispersed in aqueous medium 
followed by dispersion in the non-aqueous medium e.g., oil. In the second step of preparation, 
cross linking of the dispersed globule is carried out. The cross-linking can be achieved either by 
means of heat or by using the chemical cross linkers (gluteraldehyde, formaldehyde, calcium 
chloride, genipin etc.) 
Double Emulsion Technique 
               Double emulsion technique Double emulsion method of microspheres preparation 
involves the formation of the multiple emulsions or the double emulsion of type w/o/w and is 
best suited to the water-soluble drugs, peptides, proteins and the vaccines. This method can be 
used with both the natural as well as the synthetic polymers. The aqueous protein solution is 
dispersed in a lipophilic organic continuous phase. This protein solution may contain the active 
constituents. 
Spray Drying 
                  Spray drying serves as a microencapsulation technique when an active material is 
dissolved or suspended in a melt or polymer solution and becomes trapped in the dried particle. 
The main advantages are the ability to handle labile materials because of the short contact time in 
the dryer; in addition, the operation is economical. Applying this technique along with the use of 
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Phase Separation Coacervation Technique 
                 Phase Separation Coacervation Technique Phase separation method is specially 
designed for preparing the reservoir type of the system to encapsulate water soluble drugs e.g. 
peptides, proteins. Some of the preparations are of matrix type particularly, when the drug is 
hydrophobic in nature e.g. steroids. In matrix type device, the drug or the protein is soluble in the 
polymer phase. The process is based on the principle of decreasing the solubility of the polymer 
in the organic phase to affect the formation of the polymer rich phase called the ‘coacervates’.  
In this technique the polymer is first dissolved in a suitable solvent and then drug is dispersed by 
making its aqueous solution, if hydrophilic or dissolved in the polymer solution itself, if 
hydrophobic. Phase separation is then accomplished by changing the solution conditions by 
using any of the method mentioned. Salt addition Non-solvent addition addition of in-compatible 
polymer Change in pH the process is carried out under continuous stirring to control the size of 
the microparticles8. 
Interfacial Cross Linking 
 
                Interfacial cross-linking is derived from interfacial polycondensation, and was 
developed to avoid the use of toxic diamines, for pharmaceutical or cosmetic applications. In this 
method, the small bifunctional monomer containing active hydrogen atoms is replaced by a 
biosourced polymer, like a protein. When the reaction is performed at the interface of an 
emulsion, the acid chloride reacts with the various functional groups of the protein, leading to the 
formation of a membrane. The cross-linked protein microcapsules are biocompatible and 
biodegradable, and the presence of the protein backbone renders the membrane more resistant 
and elastic than those obtained by interfacial polycondensation10. The method is very versatile, 
and the properties of the microcapsules (size, porosity, degradability, mechanical resistance) can 
be easily tuned by varying the preparation parameters. A carbohydrate can be added to the 
protein, for the modulation of particle biodegradability. 
Complex Coacervation 
              Complex coacervation is the spontaneous liquid-liquid phase separation that frequently 
occurs when solutions of oppositely charged polyelectrolytes are mixed in the same solvent 
(usually water). It is encountered in biological systems and differs fundamentally from the 
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polymer-polymer incompatibility mentioned earlier in that one phase contains most of the two 
polymers whereas the second phase is a dilute polymer solution. Polymer-polymer 
incompatibility yields two phases with each containing predominately one of the two polymers. 
For proper encapsulation, it is preferred to have liquid coacervates which can flow around or 
completely wrap the internal phase particles or droplets.  
Solvent Evaporation 
                   The solvent evaporation encapsulation process, depicted is a way of precipitating 
small polymer particles from an oil-in-water emulsion. The polymer is dissolved in a volatile 
organic solvent that is immiscible with water. Methylene chloride is a preferred solvent because 
of its high volatility and its capacity for dissolving a broad range of polymers. A number of 
solvents that can be used and, it should be noted that, many solvents suitable for this process 
have a finite degree of water solubility, even though they are normally classified as water-
insoluble solvents. Mixed solvents can also be used. The mixtures used so far tend to contain a 
water-immiscible solvent and a water-miscible solvent (e.g., acetone). The water immiscible 
solvent is the predominant component of the mixture. Once the desired coating polymer is 
dissolved in the organic solvent, the drug to be encapsulated is added to this solution. The drug 
agent may be a solid (crystalline or amorphous) or a nonvolatile liquid. The added drug may 
completely dissolve in the polymer solution or it may be completely insoluble and simply form a 
dispersion, suspension, or suspension-emulsion. In the latter case, the solid particles must be 
micronized so that their mean diameter is much less than the desired mean microsphere size. 
This is true for any encapsulation technique, and generally, a particle size /microsphere size ratio 
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1.6. CHARACTERIZATION OF MICROSPHERES 
Particle size, Shape and Morphology 
                       All the microspheres were evaluated with respect to their size and shape using 
optical microscope fitted with an ocular micrometer and a stage micrometer. The particle 
diameters of more than 100 microspheres were measured randomly by optical microscope. 
Scanning Electron photomicrographs of drug‐loaded microspheres were taken. A small amount 
of microspheres was spread on gold stub. Afterwards, the stub containing the sample was placed 
in the Scanning electron microscopy (SEM). A Scanning electron photomicrograph was taken at 
an acceleration voltage of 20KV. 
 
Entrapment Efficiency 
                     The capture efficiency of the microspheres or the percent entrapment can be 
determined by allowing washed microspheres to lyse. The lysate is then subjected to the 
determination of active constituents as per monograph requirement. The percent encapsulation 
efficiency is calculated using following equation 
% Entrapment = Actual content/Theoretical content x 100. 
 
Scanning Electron Microscopy (SEM) 
                     The surface morphology of blank microspheres, drug loaded microspheres and 
microspheres collected after dissolution studies were examined by a Scanning electron 
microscope (Hitachi, S-3600N, Japan). The samples were fixed on brass sub using double-sided 
tape and then gold- coated in vacuum by a sputter coater. The SEM pictures were then taken at 
an excitation voltage of 15 KV14. 
 
Swelling Index15 
                     Swelling index was determined by measuring the extent of swelling of 
microspheres in the given buffer. To ensure the complete equilibrium, exactly weighed amount 
of microspheres were allowed to swell in given buffer. The excess surface adhered liquid drops 
were removed by blotting and the swollen microspheres were weighed by using microbalance. 
The hydrogel microspheres then dried in an oven at 60°C for 5 h until there was no change in the 
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dried mass of sample. The swelling index of the microsphere was calculated by using the 
formula  
Swelling index= (mass of swollen microspheres - mass of dry microspheres/mass of dried 
microspheres) 100. 
 
In Vitro Drug Release 
                        To carry out In Vitro drug release, accurately weighed 50 mg of loaded 
microspheres were dispersed in dissolution fluid in a beaker and maintained at 37±2°C under 
continuous stirring at 100 rpm. At selected time intervals 5 ml samples were withdrawn through 
a hypodermic syringe fitted with a 0.4 µm millipore filter and replaced with the same volume of 
pre-warmed fresh buffer solution to maintain a constant volume of the receptor compartment. 
The samples were analyzed spectrophotometrically. The released drug content was determined 
from the standard calibration curve of given drug. 
 
In Vitro Diffusion Studies 
                          In Vitro diffusion studies were performed using in vitro nasal diffusion cell.  The 
receptor chamber was filled with buffer maintained at 37±2°C. Accurately weighed microspheres 
equivalent to 10 mg were spread on sheep nasal mucosa. At selected time intervals 0.5 ml of 
diffusion samples were withdrawn through a hypodermic syringe and replaced with the same 
volume of prewarmed fresh buffer solution to maintain a constant volume of the receptor 
compartment. The samples were analyzed spectrophotometrically. 
 
Accelerated Stability Studies 
                          The preparation was divided into 3 sets and stored at 4°C (refrigerator), room 
temperature and 40°C (thermostatic oven). After 15, 30 and 60 days drug content of all the 
formulation was determined Spectrophotometrically. 
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LITERATURE REVIEW  
Santanu Chakraborty et al., (2010) prepared microparticles of aceclofenac by gelation 
technique using a blend of sodium alginate and carbopol 934 as release retardant. The 
entrapment efficiency was found within the range of 73.6 ± 3.21% to 90.7 ± 2.48%. All the 
formulations were investigated for various evaluation parameters like particle size, flow 
behavior, percentage swelling, surface morphology study and in vitro drug release etc. All the 
formulation showed good flow behavior as compared to the pure drug. SEM study revealed that 
the spheres were almost spherical in shape with rough outer surface. In-vitro drug release study 
showed that by increasing the polymer concentration the drug release of all the formulation were 
gradually decreased and the optimized formulation (F7) was able to sustain the drug release for 
12 hours15.  
 
Ying Lu, Guoqing Zhang et al., (2007) prepared Flubiprofen gelatin microspheres (FP-GMS) 
by an emulsion-congealing method. The particle size of FP-GMS with optimized formulation 
was 2.5, 12.3µm with a mean size of gelatin microspheres of 7.53µm. The drug loading 
efficiency was 5.02% (w/w). A total of 96% original FP was remained in the microspheres after 
being stored under 75% humidity and 37°C for 3 months. These data indicate that the simple 
emulsion-congealing method can be used to encapsulate water soluble drugs16. 
Anand kumar et al., (2011) prepared controlled release of Lamivudine microspheres by W/O/W 
multiple emulsion solvent evaporation technique using osmogen like sodium chloride, polymers 
like ethyl cellulose, cellulose acetate and polyvinyl alcohol as a continuous phase. The prepared 
microspheres were characterized for the percent drug content, encapsulation efficiency, FTIR, 
scanning electron microscopy (SEM), In vitro dissolution studies, in vitro kinetic studies and 
accelerated stability studies17. The release kinetics data and characterization studies indicate that 
drug release from microspheres was diffusion-controlled and that the microspheres were stable. 
S. S. Bansode et al., (2010) studied the preparation, properties and uses of individually 
encapsulated novel small particles, as well as significant improvements to tried-and-tested 
techniques relevant to micro and nanoparticles and their use in a wide variety of industrial, 
engineering, pharmaceutical, biotechnology and research applications. Its scope extends beyond 
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conventional microcapsules to all other small particulate systems such as self assembling 
structures that involve preparative manipulation. The review covers encapsulation materials, 
physics of release through the capsule wall and desorption from carrier, techniques of 
preparation, many uses to which microcapsules are put. 
 
P.V. Kozlov et al., (1983) studied Structural diversity of gelatin chain units determines the 
specific features of gelatin properties. Most synthetic polymers show no such features that are 
typical of most biopolymers. The first peculiarity of gelatin common to all biopolymers arises 
from the presence of both acidic and basic functional groups in the gelatin macromolecules. The 
second peculiarity of gelatin is its capacity to form a specific triple-stranded helical structure not 
observed in synthetic polymers. The third peculiarity of gelatin as a biopolymer is its specific 
interaction with water which is different to that observed with synthetic hydrophilic polymers18. 
Vikas Parashar et al., (2010) prepared Bovine Serum Albumin microspheres in four batches. 
The emulsion cross-linking method was used for the preparation. The quantity of BSA varies for 
each formulation. The microspheres were spherical, discrete and compact and size distribution 
was between 33.28 to 36.25 µm. In vitro studies were carried out at different pH for a period of 
18 h and compared with marketed formulation. From all the batches it is concluded that when 
concentration of polymer increases microspheres shows more controlled and prolonged release19. 
Satish Balakrishna Bhise et al., (2005) developed RIF’s loaded porous microspheres as a 
controlled release dosage form. Eudragit based porous microspheres of RIF were prepared by 
emulsion solvent diffusion method. Prepared porous microspheres were evaluated for its 
entrapment efficacy, morphology, thermal behavior, crystalline nature, in-vitro drug release and 
stability in simulated gastric fluid20. In vitro drug release studies indicated that drug to polymer 
ratio of 2:1 showed more than 85% drug release over the period of 3hrs. 
Hongyao Zhang et al., (2006) developed polylactic-co-glycolic acid (PLGA) microspheres for 
continuous delivery of dexamethasone acetate (DMA) for a one-month period. Methods: The 
microspheres were prepared using an oil-in-water emulsion technique. The release of DMA from 
optimized PLGA microspheres showed a biphasic pattern. DMA was released immediately 
during the initial phase then, following this initial burst release, the microsphere system then 
released the drug in a continuous fashion21. 
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Sunil K. Jain et al., (2004) studied microsphere dosage forms have gained increasing 
importance as oral controlled drug delivery systems. These systems present several advantages in 
comparison to unit dosage forms such as more predictable gastric emptying and less local 
irritation. Microsphere systems also minimize the possible intestinal retention of undigested 
polymer materials in chronic dosing. The Eudragits are a family of polymers based on acrylic 
and methacrylic acids suitable for use in orally administered drug delivery systems22. 
Kishore Narra et al., (2009) prepared the rifampicin loaded sodium alginate beads by ionic 
gelation method. In this method, various formulation variables such as the addition of PVA to 
the drug-alginate mixture and addition of PVP to cross linking solution were studied. PVA and 
PVP can be used in the formulation to improve in-vitro characteristics of rifampicin loaded 
alginate beads23. 
Sanat Kumar Basu et al., (2009) prepared Microspheres (MS) of Ketorolac Tromethamine 
(KT) for oral delivery were prepared by complex coacervation (method-1) and simple 
coacervation (method-2) methods without the use of chemical cross–linking agent 
(glutaraldehyde) to avoid the toxic reactions and other undesirable effects of the chemical cross-
linking agents. Alternatively, ionotropic gelation was employed by using sodium-
tripolyphosphate (Na-TPP) as cross linking agent. Chitosan and gelatin B were used as polymer 
and copolymer respectively24. 
Bhaskar Mazumder et al., (2009) studied the micro particles mean particle size, percentage 
yield were decreased significantly with decrease in drug-polymer ratio, surfactant concentration, 
stirring speed and volume of continuous phase. It was found that in vitro release were decreased 
significantly with decrease in drug-polymer ratio and stirring speed but increased significantly 
with increase in surfactant concentration and volume of continuous phase25. 
Chowdary K.P.R et al., (1989) carried out microencapsulation of aspirin, diazepam and 
nitrofurantoin by calcium alginate. The microparticles were found to be discrete, spherical and 
free flowing. The release mechanism was found to be of diffusion type and release depended on 
solubility of the core material in the dissolution fluid43. 
Kakkar A.P et al., (1995) developed and characterized ibuprofen loaded microcapsules with 
sodium alginate and calcium chloride by ionotropic gelation technique. Spherical, smooth 
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surfaced alginate microcapsules of ibuprofen were obtained by this method. The preparation was 
based on dispersion of sodium alginate-ibuprofen matrix in liquid paraffin followed by coating 
process by calcium chloride44.  
Prasant K Rout et al., (2009) describes preparation of microspheres by solvent evaporation and 
W/O emulsion solvent evaporation methods followed by in vitro characterization of 
microspheres to evaluate the effect of method of preparation on physical properties and drug 
release profile of microspheres. The mean geometric particle size of microspheres prepared by 
solvent evaporation method was found in the ranges of 40-50 µm and the microspheres prepared 
by W/O emulsion solvent evaporation method was found in a ranges of 126-150µm, 
respectively26. 
Alf Lamprecht, Ulrich Schafer et al., (2000) demonstrated the potential of confocal laser 
scanning microscopy as a characterization tool for different types of microparticles which are 
prepared by various methods including complex coacervation ,spray drying, double emulsion 
solvent evaporation technique and ionotropic gelation technique45.  
LakshmanaPrabu S et al., (2009) studied that drug:polymer ratio had a considerable effect on 
the entrapment efficiency, however particle size distribution of microspheres was more 
dependent on the volume of dichloromethane and polyvinyl alcohol concentration rather than on 
the drug: polymer ratio. Drug, polymer concentrations were varied to obtain optimum release 
profile for sustaining the action of the drug27. 
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                                              AIM AND OBJECTIVE 
AIM  
  The main aim of present work is to develop Lisinopril dihydrate loaded Gelatin 
microspheres by using Coacervation phase separation technique. Oral bioavailability of 
Lisinopril dihydrate is 25-28%. Dose of  Lisinopril is 10-80mg per day, thus conventional dosage 
form has several draw backs, so the main aim behind this work is to retard the release of drug at 
controlled rates throughout the day and to improve bioavailability as well as patient compliance 
by using gelatin and other polymer mixtures and to reduce dosage frequency. 
 
OBJECTIVES 
  Lisinopril dihydrate is an angiotensin-converting enzyme used in the treatment of 
hypertension, myocardial infarction, heart failure. It is used in dose of 10-80 mg twice daily. 
             The present study “Lisinopril microparticles by coacervation phase separation 
technique” was meticulously designed to improve the therapeutic efficacy and to prolong its 
release. 
              The following experimental protocol was therefore designed to allow systemic approach 
to the study: 
1) Compatibility study- compatibility with various polymers by using IR 
2) Preparation of standard curve for Lisinopril dihydrate in phosphate buffer (pH 7.4) 
3) To prepare microparticles of Lisinopril dihydrate using polymers gelatin, carbopol and 
sodium alginate by using coacervation phase separation technique. 
4) The following evaluation parameters were carried out based on laboratory experiments: 
a) Drug entrapment efficiency 
b) Flow property of prepared microparicles 
c) In-vitro dissolution studies by using dissolution tester USP (XXIII) basket method 
release. 
d) Analysis by scanning electron microscopy (SEM) 
e) Particle size analysis by optical microscope method. 
         The objectives of proposed study are as follows: 
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• To overcome the rapid elimination of drug and to develop the oral controlled drug 
delivery system. 
• To increase the biological half life of the drug or to maintain the constant drug 
concentration in the body. 
 
              The gelatin polymer was selected to prepare microspheres due to its simplicity, low cost 














PLAN OF WORK 
 
Padmavathi College of Pharmacy and Research Institute  25 
 
PLAN OF WORK 
         Present work was carried out to design and evaluate the Lisinopril dihydrate loaded gelatin 
microspheres. 
1) Selection of drug 
2) Literature review 
3) Preformulation studies 
 
a) Identification of drug 
 physical appearance 
  melting point                                               
 FT-IR spectra 
b) Solubility studies  
c) Partition coefficient 
d)  FT-IR study for drug excipient interaction 
e) Determination of absorption maxima (λ max) 
 
4) Preparation of standard curve in phosphate buffer pH 7.4 
5) Preparation of gelatin loaded microspheres 
6) Characterization of prepared gelatin microspheres 
• Yield of production 
• percent entrapment efficiency 
• particle size analysis 
• surface morphology by scanning electron microscopy (SEM) 
7) Characterization of prepared gelatin microspheres of Lisinopril dihydrate 
                       a) Angle of repose 
                       b) Bulk density 
                       c) In-vitro dissolution studies in phosphate buffer 7.4 pH buffer 
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                        d) Interpretation of drug release mechanism by kinetic models 
• Zero-order 
• First order 
• Higuchi model 
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                            MATERIALS AND METHODS 
The following materials were used as supplied by the manufacturers without further purification: 
Table No.2 
5.1. Materials Used For Formulations 
S. No Ingredients Supplied by 
1.  Lisinopril dihydrate Watson pharmaceuticals, Hyderabad. 
2.  Gelatin B Supra pharmaceuticals Ltd. Hyderabad. 
3.  Carbopol 934P NF Supra pharmaceuticals Ltd. Hyderabad. 
4.  Sodium alginate Supra pharmaceuticals Ltd. Hyderabad. 
5.  Seasame oil Yeluri formulations, Hyderabad. 
6.  Formaldehyde S.D Fine chem. Ltd, Mumbai.  





                                        
EXPERIMENTAL INVESTIGATION 
 




S.No. Equipments Manufacturer 
1. Remi stirrer No.1A323 Titan Scales Ltd. 
2. Electronic Weighing Balance Electro labs, India 
3. UV-Visible spectro photometer Shimadzu  
4. Dissolution test apparatus USP Rotating basket dissolution. 
5. Scanning electron microscope JSM 35 CF, JEOL, Japan 
6. FT-IR spectrometer Shimadzu 
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5.2 DRUG PROFILE 
Lisinopril Dihydrate 
                Lisinopril dihydrate is a lysine derivative, an oral angiotensin-converting enzyme 
(ACE) inhibitor. 
 Chemical Name    
 
(S)-1-(N2-(1-Carboxy-3-phenylpropyl)-L-
lysyl)-L-proline       dihydrate 
 
Molecular Weight                                                  441.52                                   
 
Structural Formula 
                                        
Category                   Antihypertensive 
Appearance                                                            white to off-white, crystalline powder 
Solubility                            It is soluble in water, sparingly soluble in 
methanol, and practically insoluble in 
ethanol. 
Melting Point                                   Around 160 ̊C 
Storage                                                           Stored in air tight and light resistant  
                                                                                     container. 
EXPERIMENTAL INVESTIGATION 
 
Padmavathi College of Pharmacy and Research Institute 30 
 
Pharmacokinetics 
                         Following oral administration of Lisinopril, peak serum concentrations of 
Lisinopril occur within about 7 hours. Lisinopril does not appear to be bound to other serum 
proteins. Lisinopril does not undergo metabolism and is excreted unchanged entirely in the urine. 
Declining serum concentrations exhibit a prolonged terminal phase which does not contribute to 
drug accumulation. This terminal phase probably represents saturable binding to ACE and is not 
proportional to dose. Systemic bioavailability of Lisinopril dihydrate is approximately 25%28. 
 
• DOSE                                                           : 5-80mg daily 
• ONSET OF ACTION                                  : 1Hour 
• PEAK PLASMA CONCENTRATION       : 6 Hours 
• BIOAVAILABILITY                                  : 25%-28% 
• EXCRETION                                               : Unchanged in urine 
• HALF LIFE ELIMINATION                      : 12 HOURS on multiple dosing. 
• PROTEIN BINDING                                   : Doesn’t bound to serum proteins 
• VOLUME OF DISTRIBUTION                  : 28ML/MIN 
 
•   Mechanism of Action 
                     The mechanism through which Lisinopril lowers blood pressure is believed to be 
primarily suppression of the renin-angiotensin-aldosterone system, Lisinopril is antihypertensive 
even in patients with low-renin hypertension. Lisinopril inhibits angiotensin-converting enzyme 
(ACE) in human subjects and animals. ACE is a peptidyldipeptidase that catalyzes the 
conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also 
stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of Lisinopril in 
hypertension and heart failure appear to result primarily from suppression of the renin-
angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II 
which leads to decreased vasopressor activity and to decrease aldosterone secretion28. The latter 
decrease may result in a small increase of serum potassium. In hypertensive patients with normal 
EXPERIMENTAL INVESTIGATION 
 
Padmavathi College of Pharmacy and Research Institute 31 
 
renal function treated with Lisinopril alone for up to 24 weeks, the mean increase in serum 
potassium was approximately 0.1mEq/L29. 
          
                                                        Fig.No.2 
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SIDE EFFECTS 
 First doses of Lisinopril can cause dizziness due to a drop in blood pressure. 
 Lisinopril can cause nausea, headaches, anxiety, insomnia, drowsiness, nasal congestion, 
and sexual dysfunction.  
 Like all ACE inhibitors, Lisinopril may cause a nonproductive cough that resolves when 
the drug is discontinued. 
 Lisinopril should be stopped if there are symptoms or signs of an allergic reaction 
including feelings of swelling of the face, lips, tongue or throat. Severe allergic reactions 
(anaphylaxis) and hives occasionally occur. (Ref FDA). 
 Rarely, Lisinopril may cause a decrease in red blood cells (anemia), white blood cells 
(leukopenia), and platelets (thrombocytopenia). 
 
CONTRAINDICATIONS 
Pregnancy: Lisinopril should not be taken during pregnancy because fetuses and neonates 
have died when Lisinopril was administered during pregnancy29. 
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5.3 EXCIPIENT PROFILE 
    5.3.1. Gelatin Type B 
       Gelatin type B, with isotonic point of 4.8 to 5.2, is the result of an alkaline pretreatment 
of the collagen. Gelatin is a heterogeneous mixture of single or multi-stranded polypeptides, each 
with extended left-handed proline helix conformations and containing between 50 - 1000 amino 
acids. Gelatin is produced by partial hydrolysis of collagen extracted from the boiled bones, 
connective tissues, organs and some intestines of animals such as domesticated cattle, and pigs32. 
Type A gelatin (dry and ash free) contains 18.5 % nitrogen, but due to the loss of amide groups, 
Type B gelatin contains only about 18% of nitrogen. 
            Gelatin melts to a liquid when heated and solidifies when cooled again. Together with 
water, it forms a semi-solid colloid gel. Gelatin forms a solution of high viscosity in water, 
which sets to a gel on cooling, and its chemical composition is, in many respects, closely similar 
to that of its parent collagen.  
           Gelatin is an amphoteric protein with isotonic point between 5 and 9 depending on raw 
material and method of manufacture. Like its parent protein, collagen, it is unique in that it 
contains 14% hydroxyproline, 16 % proline and 26 % glycine.  
           The cross-linking of gelatin with aldehydes is being used to extend the uses of gelatin. In 
particular, treatment of gelatin films with glutaraldehyde is receiving considerable study in order 
to improve their thermal resistance, decrease their solubility in water as well as to improve their 
mechanical properties. 
           Solution pH (1%) is usually about pH 5 but can vary considerably. At this pH the 
viscosity of Type B gelatin is minimal and the gel strength is maximal, hence from the 
manufacturers’ point of view it is advantageous to manufacture gelatin at this pH30. 
           The most important attribute of gelatin is its gel strength and when determined by the 
standard method, is called the Bloom Strength. This is the force in grams required to press a 12.5 
mm diameter plunger 4 mm into 112 g of a standard 62/3% w/v gelatin gel at 10°C30. Several 
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penetrometer type instruments have been adapted to determine Bloom Strength. In the present 
work the bloom strength of gelatin B used was 250. 
Structure of gelatin 
 
 
Empirical formula of gelatin  
Gelatin contains many glycine (almost 1 in 3 residues, arranged every third residue), 
proline and 4-hydroxyproline residues. A typical structure is  -Ala-Gly-Pro-Arg-Gly-Glu-4Hyp-
Gly-Pro-. 
Synonyms 
            Gelatine, Jelly, gel. 
Solubility  
The solubility of the gelatin is determined by the method of manufacture30.  The rate 
of solubility is affected by factors such as temperature, concentration and particle size. Gelatin is 
insoluble in cold water but swells and softens when immersed in it, gradually absorbing 5-10 
times water to its weight. Soluble in hot water, 6N acetic acid. Insoluble in alcohol, ether and 
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Functional categories 
USP: Suspending agent, viscosity increasing agent, gelling agent, stabilizer30. 
IP: gelling agent ,   thickener ,  film former ,  protective colloid ,  adhesive agent , stabilizer ,  
emulsifier. 
Others:  Foaming/whipping agent, beverage fining agent, gelling agent in food and cosmetic 
manufacturing. 
Method of manufacture 
Gelatin is made from by-products of the meat and leather industry. Gelatin is derived 
mainly from pork skins, pork and cattle bones, or split cattle hides. The raw materials are 
prepared by different curing, acid, and alkali processes which are employed to extract the dried 
collagen hydrolysate30. These processes may take up to several weeks, and differences in such 
processes have great effects on the properties of the final gelatin products. 
The manufacturing processes of gelatin consist of three main stages: 
1. Pretreatments to make the raw materials ready for the main extraction step and to remove 
impurities which may have negative effects on physiochemical properties of the final 
gelatin product, 
2. The main extraction step, which is usually done with hot water or dilute acid solutions as 
a multi-stage extraction to hydrolyze collagen into gelatin, and finally, 
3. The refining and recovering treatments including filtration, clarification, evaporation, 
sterilization, drying, rutting, grinding, and sifting to remove the water from the gelatin 
solution, to blend the gelatin extracted, and to obtain dried, blended and ground final 
product. 
Stability and storage conditions 
Dry gelatin has an almost infinite shelf life as long as the moisture content is such as to 
ensure that the product is stored below the glass transition temperature30. 
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 The stability of gelatin in solution depends on temperature and pH. Generally, to 
minimize loss of gel strength and viscosity with time, the pH of the solution should be in the 
range 5 to 7 and the temperature should be kept as low as possible, consistent with the avoidance 
of gelation and the suitability of the solution viscosity to the particular application. 
Safety 
             Gelatin is regarded as a food ingredient rather than an additive and it is Generally 
Regarded as Safe (GRAS). In 1993 the FDA reiterated the GRAS status of gelatin and stated that 
there was no objection to the use of gelatin from any source and any country provided that the 
hide from animals showing signs of neurological disease were excluded and also Specified Raw 
Materials were excluded from the manufacturing process. 
Application in pharmaceuticals 
Microencapsulation: Gelatin is amphoteric, i.e. it has both positive and negative charges on 
the molecule (and no net charge at the isoionic point). Hence, at a pH where the basic side chains 
do not carry a charge, acid groups for example from gum arabic can react with the basic groups 
of gelatin to form an insoluble gelatin-arabate complex which can be precipitated around 
emulsified oil droplets, forming micro-ecapsulated oil. The microcapsules are hardened with 
formaldehyde or gluteraldehyde before harvesting and drying31. 
Milk – Food stabilizing industry: Gelatin is used as a stabilizer particularly in yoghurt, 
where the addition of 0.3 - 0.5 % acts to prevent syneresis thus allowing the production of stirred 
and fruit containing products. 
Emulsifying properties: Gelatin gives limited emulsifying and emulsion stabilising 
properties used in the manufacture of toffees and water in oil emulsions like low fat margarine31. 
Texturising properties: Gelatin is used in dried soups to provide the appropriate mouth feel 
(viscosity) to the final product. 
Film forming properties: Gelatin's film forming properties are used in the manufacture of 
both hard and soft (pharmaceutical) capsules. 
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Adhesive properties: An example of this use of gelatin is in pharmaceutical or confectionery 
tableting and in liquorices’ all-sorts where it can be used to join the layers. 
Gelling properties:  In the manufacture of these products gelatin is combined with sugar and 
glucose syrups. 
Review of past work on gelatin 
                 BSA-loaded gelatin microspheres were prepared they are with a high loading efficacy 
and a particle size from 1 to 10µm. In vitro degradation and drug release studies were performed 
in order to evaluate the potential of gelatin microspheres as regulated and sustained release 
systems. During 4 days, between 80 and 91 % of gelatin microspheres were degraded. The 
diffusion exponents were superior to 0.5 indicating the anomalous Fickian diffusion, thus 
suggesting the influence of a polymer relaxation and diffusion through the matrix in BSA 
release33. 
                 Microspheres (MS) of Ketorolac Tromethamine (KT) for oral delivery were prepared 
by complex coacervation (method-1) and simple coacervation (method-2) methods without the 
use of chemical cross–linking agent (glutaraldehyde) to avoid the toxic reactions and other 
undesirable effects of the chemical cross-linking agents. Alternatively, ionotropic gelation was 
employed by using sodium-tripolyphosphate (Na-TPP) as cross linking agent. Chitosan and 










Padmavathi College of Pharmacy and Research Institute 38 
 
5.3.2. Carbopol 934P NF (“carboxy polymethylene”) 
Structural formula 
                         
Empirical formula 
                     (C3H4O2) n 
Description  
 It is fluffy, white, dry powder (100% effective). The carboxyl groups provided by the 
acrylic acid backbone of the polymer are responsible for many of the product benefits. Carbopol 
934P NF is cross-linked with allyl sucrose and is polymerized in solvent benzene.  
Method of manufacture 
Carbomers are synthetic, high-molecular-weight, cross linked polymers of acrylic acid. 
These acrylic acid polymers are cross linked with allyl sucrose or allyl pentaerythritol. The 
polymerization solvent used previously was benzene; however, Carbopol 934P NF is cross-
linked with allyl sucrose and is polymerized in solvent benzene35. 
 
Grades 
Various grades of carbopol are available like Carbopol 71G, 971 P, 974 P, 940NF, 934P 
NF, 1342 NF, 980NF with different viscosities. For present work we used carbopol 934P NF 
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Solubility 
            Swellable in water, glycerin and after neutralization in ethanol (95%). Carbomers do not 
dissolve but merely swell to a remarkable extent, since they are three-dimensionally cross linked 
micro gels. In addition to its hydrophilic nature, its cross-linked structure and it’s essentially 
insolubility in water makes Carbopol a potential candidate for use in controlled release drug 
delivery systems. 
Stability and storage conditions 
          Carbomers are stable, hygroscopic materials that may be heated at temperatures below 
104 ̊C̊ for up to 2 hours without affecting their thickening efficiency. However, exposure to 
excessive temperatures can result in discoloration and reduced stability. Dry powder forms of 
carbomer do not support the growth of molds and fungi. At room temperature, carbomer 
dispersions maintain their viscosity during storage for prolonged periods. 
Safety 
         Carbomers are generally regarded as essentially nontoxic and nonirritant materials. There is 
no evidence of systemic absorption of carbomer polymers following oral administration. Acute 
oral toxicity studies in animals indicate that carbomer 934P NF has a low oral toxicity. 
Applications 
           The readily water swellable Carbopol polymers are used in a diverse range of 
pharmaceutical applications to provide: 
• Controlled release in tablets. 
• Bioadhesion in buccal, ophthalmic, intestinal, nasal, vaginal and rectal applications. 
• Thickening agent in topical, lotions, creams and gels, oral suspensions and transdermal 
gel reservoirs. 
• Permanent suspensions of insoluble ingredients in oral suspensions and topicals. 
• Emulsifying topical oil-in-water systems permanently, even at elevated 
temperatures, with essentially no need for irritating surfactants. 
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5.3.3. Sodium Alginate 
Structural formula 
                            
                        
 
Empirical formula 
                            (CH7O6Na)n 
 
Description 
Sodium alginate occurs as a
alginate produces aqueous solutions that forms gel on the addition of small amount of soluble 
calcium salt. 
Grades 
             Various grades of sodium alginate are available yielding aqueous solutions of varying 
viscosities within a range of 20-400 centipoises.
Solubility 
             Sodium alginate is very slowly soluble in water forming a viscous colloidal solution 
practically it is insoluble in alcohol, chloroform and ether and in hydro alcoholic solutions in 
which alcohol content is greater than 30% by weight.
Stability and storage conditions
             Sodium alginate is hygroscopic;
relative humidity. Dry storage stability is excellent when the powder is stored in a well closed 
container at temperatures of 25C̊ or less
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Incompatibility 
          Depending on the concentrations sodium alginate is incompatible with phenols and 
parabens37. 
           
Applications of Sodium Alginate 
• Food Application 
• Pharmaceutical Application 
• Dental application 
• Cosmetic Application 
Food Application  
        Used as an emulsifier and thickener in areas like food industry. It is also used in dairy 
products to enhance taste and flavor. 
Pharmaceutical Application   
       Sodium Alginate fibers are used to weave bandages for larger wounds and burns and are 
used as an additive in treating skin diseases. 
       Used as suspending and thickening agents aid in the preparation of water miscible pastes, 
creams and gels36. 
Dental Application  
       Commonly used by dentists. 
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                       5.4 PREFORMULATION STUDIES 
 Prior to the development of the dosage forms the preformulation study was carried out. 
Hence infrared spectra of the physical mixture of the drug and the polymers chosen were taken. 
The infrared spectra of the drug and polymers were also taken.  
             The application of infra-red spectroscopy lies more in the qualitative identification of 
substances either in pure form or in the mixtures and as a tool in establishment of the structure. 
Since IR is related to covalent bonds, the spectra can provide detailed information about the 
structure of molecular compounds. In order to establish this point, comparisons can be made 
between the spectrum of the substance and the drug. 
             The above discussions imply that infra-red data is helpful to confirm the identity of the 
drug and to detect the interaction of the drug with the carriers. 
              Preformulation studies give the information need to define the nature of the drug 
substance and provide a frame work for the drug combination with pharmaceutical excipients in 
the fabrication of a dosage form. 
 Physical appearance 
            Lisinopril dihydrate is a white to off-white, crystalline powder. 
Melting Point 
           Melting point was found around 160⁰C with decomposition. 
 Partition Coefficient 
           At room temparature (n-Octanol/0.1M pH-7 phosphate buffer) found to be 10.2±0.5. 
 Determination Of λmax 
           An absorption maximum of Lisinopril dihydrate was found to be 258nm. 
SOLUBILITY STUDIES 
The solubility of Lisinopril dihydrate was determined in solvents of different polarities. 
The solubility of Lisinopril dihydrate is usually determined by the equilibrium solubility method, 
which employs a saturated solution of Lisinopril dihydrate, obtained by adding an excess amount 
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of Lisinopril dihydrate in the solvent to promote drug precipitation, and then stirring for 24hrs 
until equilibrium reached. The mixture was filtered and amount of Lisinopril dihydrate was 
determined using UV spectrophotometer at 258nm. 
 
Table No.4 
    Solubility Studies of Lisinopril Dihydrate in Various Solvents 
 
S. No. Solvents Observed 
1 Distilled Water  Freely soluble 
2 PBS-7.4(pH) Freely soluble 
3 Ethanol Practically Insoluble  
4 Acetonitrile  Practically Insoluble 
 
5.5 STANDARD PLOT FOR LISINOPRIL DIHYDRATE: 
Standard graph by using phosphate buffer (pH 7.4) 
  Accurately weighed 10mg of Lisinopril dihydrate was dissolved in 100ml of 7.4 pH buffer 
solution to form 100mcg/ml stock solution. 
From the above stock solution aliquots of 10ml, 20ml, 30ml, 40ml, 50ml were pipetted out into a 
series of 100ml volumetric flasks and volume was made up to 100ml in order to get a concentration 
ranging from 10-50mcg/ml. 
The absorbance of the resulting solution was then measured at 258nm using UV-
Spectrophotometer against respective parent solvent as blank. The standard curve was obtained by 
plotting absorbance Vs concentration in mcg/ml.  






















1 10 0.220 
2 20 0.433 
3 30 0.617 
4 40 0.789 
5 50 0.980 
 
Graph No.1 
Calibration curve of Lisinopril dihydrate 
                  1.2                                                                               Y= 0.0178x 
        1                                                                                                     R2 = 0.9939 
                 0.8 
                 0.6   
                 0.4 
                 0.2 
                     
                            0                  10              20            30        40                50               60  
                                                                                    CONCENTRATION mcg/ml     
 Slope= 0.0178 
Calibration Curve For Lisinopril Dihydrate in Phosphate Buffer pH 7.4 at 
258nm. 
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                          FORMULATION AND DEVELOPMENT 
Preparation of Microparticles 
                
                 Gelatin, gelatin-carbopol and gelatin-sodium alginate mixture containing Lisinopril 
dihydrate Micro spheres were prepared by “coacervation phase separation technique” utilizing 
temperature change. In this method weighed amount of Gelatin was dissolved in 10ml of water 
which was previously heated to 50˚ C, to this Lisinopril was added and stirred approximately at 
300 rpm with the help of magnetic stirrer for 15 mins to get a stable dispersion.  The dispersion 
was poured drop wise into the 100ml of seasome oil which was also previously heated to 50˚ C 
on a water bath. The mixture was stirred with a help of magnetic stirrer for 2 hrs at 300rpm at 
room temperature38. 
                 
                At the end of 2 hrs cross linking agent formaldehyde 0.5ml was added to the dispersion 
medium and stirring was continued for next 30 mins. Finally it was kept in refrigerator for 24 hrs 
to ensure the rigidization of microspheres. Then the microspheres were washed with propylene 
glycol to wash off excess oil. This Procedure was followed to prepare 6 batches of Lisinopril 
microspheres with different ratios of gelatin and gelatin-carbopol, gelatin-sodium alginate 
mixtures. The amount of drug and polymers used were given in Table No.6 
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Table No.6 






















F1 20 1 - - 0.5 
F2 20 1.5 - - 0.5 
F3 20 0.75 0.25 - 0.5 
F4 20 0.50 0.50 - 0.5 
F5 20 0.75 - 0.25 0.5 












Padmavathi College of Pharmacy and Research Institute  47 
 
                                 EVALUATION STUDIES 
7.1. Particle size determination38, 39 
                 The particle size of a pharmaceutical substance is strictly maintained in order to get 
optimal biological activity. 
Methods to estimate particle size  
                                                           a. Optical microscopy 
                                                           b. Sieving method 
                                                           c. Sedimentation method 
                                                           d. Elutriation method 
                                                           e. Centrifugal defractometry 
                                                           f. Permeability method 
                                                           g. Light scattering method 
 
                                                      Table No.7 
    Common techniques for measuring fine particles of various sizes  
 
S.No Technique Particle size in µm 
1 Optical microscopy 1-100 µm 
2 Sieving >50 µm 
3 Sedimentation >1 µm 
4 Elutriation 1-50 µm 
5 Centrifugal <50 µm 
6 Permeability >1 µm 
7 Light 0.5-50 µm 
 
Particle size analysis 
                     The Particle size analysis was carried out by using optical microscopy. About 200 
Micro spheres were selected randomly and their size was determined by using optical 
microscope fitted with standard micrometer scale. The mean particle size of Micro spheres was 
given in Table No.8 
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Table No.8 
Mean Particle size of microsphere formulations 
S.No Formulation Particle size (µm) 
1 F1 67.9 
2 F2 76.4 
3 F3 69.2 
4 F4 73.7 
5 F5 68.5 
6 F6 70.3 
 
Flow properties38, 39 
                    Irregular flow of powder from the hopper produces tablets and capsules with no 
uniform weights. Flow properties depend on particle size, shape, porosity and density of the 
powder. The flow properties of microspheres were studied by determining various parameters 
like the angle of repose and bulk density. The angle of repose was determined by the fixed-base 
cone method. Bulk density is determined using digital bulk density apparatus (Electrolab, India). 
7.2. Determination Angle of Repose 
                    The flow characteristics are measured by angle of repose. Improper flow is due to 
frictional forces between the particles. These forces are quantified by angle of repose. Angle of 
repose is defined as maximum angle possible between the surface of the pile of the powder and 
the horizontal plane. The flow of powder and the angle of repose are depicted in the following 
table. 
Definition 
      Lower the angle of repose the better the flow property. Rough and irregular surface of 
particles gives higher angle of repose. Decrease in the particle size leads to a higher angle of 
repose. 
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                                          TanƟ = h/r 
                                          Ө = tan‾ 1 (h/r) 
                                           Where, h = height of pile 
                                                        r = radius of base of pile 
                                                        Ɵ = angle of repose 
Method 
        A glass funnel is held in place with a clamp on a ring support over a glass plate. The glass 
plate is placed on a stand. Approximately 100 mg of a particle is transferred into funnel keeping 
the orifice of the funnel blocked by the lower thumb. As the thumb is removed the particles are 
emptied from funnel, and the angle of repose is determined by above mentioned formula.  
                                           
                                                                     Table No.9 
Relation between Angle of Repose and Flow of the Particles 
  




>40 Very poor 
 
                                                                Table No.10 
Angle of Repose of Microparticles 
S.No Formulation Angle of repose 
1 F1 25º 40’ 
2 F2 26º 28’ 
3 F3 26 º44’ 
4 F4 24 º48’ 
5 F5 25º 34’ 
6 F6 24º 26’ 
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 7.3. Determination of Bulk Density 
              Bulk density is defined as the weight per unit volume of material. Bulk density is 
primarily used for powders or pellets. The test can provide a gross measure of particle size and 
dispersion which can affect material flow consistency and reflect packaging quantity. 
 
Table No.11 
Bulk Density of Formulations 







                        
 
7.4. DRUG ENTRAPMENT EFFICIENCY40 
              Drug entrapment efficiency of Lisinopril dihydrate was performed by accurately 
weighing 20 mg of micro particles and suspended in 20ml of simulated intestinal fluid of pH 
7.4± 0.1 and it was kept for 12hrs. Next day it was stirred for 15mins, and subjected for 
filtration. After suitable dilution, Lisinopril dihydrate content in the filtrate was analyzed 
spectrophotometrically at 258nm using Shimadzu UV-visible Spectrophotometer.  
                            
                The absorbance found from the UV-spectrophotometer was plotted on the standard 
curve to get the concentration of the entrapped drug. Calculating this concentration with the 
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Encapsulation efficiency was calculated using the following formula 
 
Theoretical drug content =   Amount of drug in bead  ×100 
                                                Amount of bead taken 
 
 
Encapsulation efficiency =   Practical drug content    x 100 
                                              Theoretical drug content 
                                                  
                                                       Table No.12 
                     Drug entrapment Efficiency of Microparticles 








7.5. Determination of Percentage yield of microspheres 
                  Thoroughly dried microspheres were collected and weighed accurately. The 
percentage yield was then calculated using formula  
 
              % Yield = Mass of microspheres obtained  ×100 
                              Total weight of drug and polymer 
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Table No.13 
Percentage yield of formulations 
Formulation 
 














7.6. SCANNING ELECTRON MICROSCOPY 
    Procedure 
                Morphology details of the specimens were determined by using a scanning electron 
microscope (SEM), Model JSM 35CF, JEOL, Japan. The samples were dried thoroughly in 
vacuum desiccator before mounting on brass specimen studies. The samples were mounted on 
specimen studies using double sided adhesive type, and gold palladium alloy of 120Å knees was 
coated on the sample using sputter coating unit (Model E5 100 Polaron U.K) in Argon ambient 
of 8-10 Pascal with plasma voltage about 20MA. The sputtering was done for nearly 3mins to 
obtain uniform coating on the sample to enable good quality SEM images. The SEM was 
operated at low accelerating voltage of about 15KV with load current of about 80 MA. 
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               The condenser lens position was maintained in between 4.4 - 5.1. The objective lens 
aperture has a diameter of 240 microns and the working distance WD=39mm41, 42. 
            
          
                   Fig No.3 SEM of Formulation F4 under Low Magnification 
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                       Fig No.4 Surface View of Microsphere of Formulation F4 
 
                           
 
 
7.7. FT-IR Spectra of Lisinopril Dihydrate 
                         The FT-IR analysis of the Lisinopril dihydrate was carried out for quantitative 
compound identification. The FT-IR graph was taken in the range of 4000cm-1 – 450cm-1 and 
with the resolution 4cm-1. The FT-IR spectra for pure drug was obtained by KBr pellet method 
and also was employed to detect chemical interaction between drug and polymers and results 
were given in below table and graphs. 













Comparision of IR Spectra of Lisinopril dihydrate and in combination with 
polymers 
 















1 Lisinopril dihydrate 
(LDH) 
3296.32 3555.59 1658.99 1343.12 2964.39 
2 LDH + Gelatin 
 
3295.51 3556.59 1658.48 1343.11 2964.02 
3 LDH + Carbopol 
 
3295.45 3556.48 1658.90 1343.14 2964.15 
4 LDH + Sodium 
alginate 
3296.33 3555.16 1658.95 1343.10 2964.10 
 



















   Graph No.2 
 















            
                                                              Graph no.3 
 










FT-IR graph of Lisinopril dihydrate + Carbopol 
 
                        
 
                 Spectrum name: Lisinopril dihydrate + carbopol.sp 
           
          Lisinopril dihydrate + carbopol.pk 
 
                          3295.45 
                          3556.48 
                          1658.90 
                          1343.14 
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                                                     Graph No.5 
 






                 Spectrum name: Lisinopril dihydrate+sodium alginate.sp 
           
  Lisinopril dihydrate+sodium alginate.pk 
 
                     3296.33 
                     3555.16 
                     1658.95  
                     1343.10  
                     2964.10 
EVALUATION STUDIES 
 
Padmavathi College of Pharmacy and Research Institute  60 
 
                       7.8. IN-VITRO DISSOLUTION STUDIES 
           A drug is expected to release from the solid dosage forms (granules, tablets, 
microspheres, capsules etc.) and immediately go into molecular solution. This process is called 
as dissolution. 
Drug release studies 
            The method specified in USP for the drug release study was followed. 
Apparatus 
              USP XXIII dissolution test apparatus employing the round bottom dissolution vessel 
and rotating basket assembly. 
Buffer stage 
             900ml of pH 7.4 and intestinal fluid Ts (phosphate buffer) 
Time 
             For every 2 hrs interval samples were taken and this was continued till 18 hrs. 
Procedure 
             In-vitro release profile of the microparticles was evaluated using rotating basket 
dissolution apparatus. 900ml of phosphate buffer (pH 7.4) maintained at 37 ± 0.5° C was used as 
dissolution medium, and the basket was rotated at a constant speed of 75 rpm. Accurately 
weighed amount of microparticles equivalent to 20 mg of drug were placed in baskets. 
             Aliquots of samples were withdrawn at the interval of 2 hrs for 18 hrs in phosphate 
buffer pH 7.4. The samples withdrawn were filtered, diluted suitably and analyzed at 258nm 
spectrophotometrically for drug release.    
 
7.9. Kinetics of drug release 
              The data obtained from the in-vitro dissolution studies was subjected for kinetic 
treatment to obtain the order of release and best fit model for the formulations. 
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                                                    Table No.15 













2 0.022 1.25 2.2 11.3 
4 0.049 2.77 5.0 25 
6 0.099 5.61 10.1 50.5 
8 0.113 6.36 11.4 57.3 
10 0.125 7.04 12.6 63.4 
12 0.136 7.67 13.8 69.1 
14 0.146 8.24 14.8 74.2 
16 0.157 8.85 15.9 79.7 
18 0.168 9.44 17 85 
                                                            
                                                          Graph No.6 
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                                                       Table No.16 













2 0.027 1.53 2.76 13.8 
4 0.042 2.36 4.26 21.3 
6 0.080 4.53 8.16 40.8 
8 0.011 6.18 11.1 55.7 
10 0.123 6.92 12.4 62.3 
12 0.130 7.35 13.6 68.2 
14 0.141 7.97 14.3 71.8 
16 0.150 8.43 15.1 75.9 
18 0.157 8.82 15.8 79.4 
                                                               
                                                                 Graph No.7 
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Table No.17 













2 0.022 1.25 2.26 11.3 
4 0.039 2.22 4.0 20 
6 0.089 5.00 9.0 45 
8 0.119 6.72 12.1 60.8 
10 0.124 7.00 12.6 63.1 
12 0.131 7.4 13.3 66.7 
14 0.137 7.7 13.8 69.3 
16 0.139 7.8 14.1 70.5 
18 0.143 8.0 14.5 72.8 
                                         
Graph No.8 
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                                                             Table No.18 













2 0.018 1.02 1.84 9.2 
4 0.051 2.88 5.2 26 
6 0.091 5.14 9.26 46.3 
8 0.106 5.96 10.7 53.7 
10 0.119 6.72 12.1 60.5 
12 0.131 7.36 13.2 66.3 
14 0.141 7.93 14.2 71.4 
16 0.151 8.53 15.3 76.8 
18 0.163 9.16 16.5 82.5 
 
Graph No.9 
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                                                              Table No.19 













2 0.023 1.34 2.42 12.1 
4 0.043 2.42 4.36 21.8 
6 0.075 4.23 7.62 38.1 
8 0.098           5.52 9.94 49.7 
10 0.110 6.21 11.1 55.9 
12 0.120 6.74 12.1 60.7 
14 0.129 7.25 13.0 65.3 
16 0.139 7.83 14.1 70.5 
18 0.148           8.35 15.0 75.2 
 
                                                            Graph No.10 
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                                                               Table No.20 













2 0.029 1.63 2.94 14.7 
4 0.054 3.04 5.48 27.4 
6 0.066 3.75 6.76 33.8 
8 0.091 5.16 9.30 46.5 
10 0.108 6.10 10.5 54.9 
12 0.129 7.22 13 65 
14 0.131 7.36 13.26 66.3 
16 0.136 7.68 13.8 69.2 
18 0.142 8.0 14.4 72.1 
                                                             
                                                               Graph No.11 










































Comparative cumulative percentage release profile of                                                 




Cumulative percentage drug release (%) 
F1 F2 F3 F4 F5 F6 
2 11.3 13.8 11.3 9.2 12.1 14.7 
4 25 21.3 20 26 21.8 27.4 
6 50.5 40.8 45 46.3 38.1 33.8 
8 57.3 55.7 60.8 53.7 49.7 46.5 
10 63.4 62.3 63.1 60.5        55.9 54.9 
12 69.1 68.2 66.7 66.3 60.7 65 
14 74.2 71.8 69.3 71.4 65.3 66.3 
16 79.7 75.9 70.5 76.8 70.5 69.2 

















Comparative dissolution profile of formulations 
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Zero order plot for formulation F6





















First order plot for formulation F6
EVALUATION STUDIES 
 
Padmavathi College of Pharmacy and Research Institute  70 
 
                                    
Graph No.15 
 
                                
Graph No.16 
 
                                       
 

























Korsmeyer peppas plot for formulaton F6




































squre root of time
Higuchi plot for formulation F6 
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zero order plot for formulationF2





















First order plot for formulation F2
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squre root of time
Higuchi plot for F2 


































korsmeyer pappas plot for formulationF2
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R2 R2 R2 R2 n 
F1 0.9618 0.9899 0.9908 0.9836 0.5892 Non-fickian, higuchi 
F2 0.9136 0.8885 0.9701 0.9801 0.5962 Non-fickian, higuchi, 
first order. 
F3 0.9604 0.9913 0.9882 0.9882 0.5847 Non-fickian, first 
order, higuchi. 
F4 0.9414 0.9774 0.9768 0.9849 0.5834 Non-fickian, higuchi, 
first order. 
F5 0.9666 0.8539 0.9950 0.9877 0.5728 Non-fickian, higuchi, 
first order.  
F6 0.9416 0.9018 0.9782 0.9948 0.5475 Non-fickian, higuchi, 
zero order. 
 
R2= Regression coefficient  n=slope   
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ACCELERATED STABILITY STUDIES 
            The formulations were stored in a oven at 37 ± 2˚C and 65% RH for a period of six 
weeks. The samples were analyzed for drug content every week by spectrophotometer at 
258nm. 
Method 
            Microspheres of formulations F1 and F5 were individually wrapped using aluminium 
foil and packed in ambered color screw cap bottle and put at above specified condition in 
incubator for 45 days.  After 45 days microspheres were evaluated for percentage drug 
content. 
Table No.23 
         Stability Studies of Percentage Drug Content of Formulation F1 & F5 
Days F1 F5 
37C̊&65%RH 60C̊ 37C̊&65%RH 60C̊ 
1 60.74 60.70 83.20 83.09 
7 59.57 58.23 82.12 81.98 
14 56.29 55.03 81.09 80.02 
21 55.09 54.18 80.45 79.23 
38 54.13 53.21 78.97 78.54 
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                                RESULTS AND DISCUSSION 
                      In this present work efforts have been made to develop gelatin loaded microspheres 
of Lisinopril dihydrate using “Coacervation phase separation technique” using biogenic 
polymers gelatin, sodium alginate and carbopol. 
                     In the present work, total six formulations were prepared and the detailed 
composition is shown in Table No.6. The prepared microparticles were subjected to 
granulometric study, angle of repose, scanning electron microscopy, drug entrapment efficiency, 
In-vitro dissolution and stability studies.   
Micromeritic Properties of Microspheres 
                      Flow properties of the prepared microspheres were determined by conducting 
Angle of repose, Bulk density determinations shown in Table No.10, 11. Angle of repose of F1, 
F4& F6 formulations are below 25 and shows excellent flow properties remaining are having 
good flow properties. The prepared Lisinopril Dihydrate microspheres were subjected to bulk 
density test and the result indicates good packing property. Among all formulations F6 has 
shown good micromeritic properties. 
 
Drug Polymer Interaction (FTIR) Study 
                      To check the compatibility of the drug with various polymers, IR spectra of the 
drug, polymers and combination of the drug and polymers were taken. The IR spectra of the drug 
and their combinations with polymers are shown in Graph No. 2-5. The characteristic major 
peaks of Lisinopril dihydrate were obtained at 3296.32 cm-1, 3555cm-1, 1658.99cm-1, 1302.02cm-
1
 and 1420.69cm-1. The values of peaks of drug and its combination with polymers were shown 
in the Table No.14. It was observed that all the major peaks of Lisinopril dihydrate were intact 
when it was in combination with polymers and no considerable changes in the IR peaks were 




RESULTS AND DISCUSSION 
Padmavathi College of Pharmacy and Research Institute  76 
 
Percentage Yield of Formulations 
                  The percentage yield of microspheres of all the formulations was in the range of 
78.90% to 88.53% shown in the Table No.13. The microspheres prepared by this method were 
found to be discrete, spherical, free flowing and it was observed by Scanning Electron 
Microscopy (SEM) Figure No.3. 
Drug Entrapment Efficiency of Microspheres 
                  The entrapment efficiency was in the range of 60.78 to 88.24% shown in Table 
No12. The formulations F6 and F5 were shown high entrapment efficiency of 83.24% & 82.76% 
which were made by combination of gelatin and sodium alginate polymers. The mean particle 
sizes of formulations were in the range of 67.9-76.4 µm. It was mentioned in Table No.8. The 
shape of the Microspheres shows smooth surface. 
In vitro Drug Release Studies        
                   Dissolution profile of gelatin containing Lisinopril dihydrate Microspheres in 
Phosphate buffer pH 7.4 showed that Micro spheres with low amount of gelatin released 85.0% 
(F1) of Lisinopril after 18 hrs while Micro spheres prepared with high amount of gelatin released 
only 79.4% (F2) of Lisinopril. The In-vitro Dissolution profile of gelatin-carbopol containing 
Lisinopril dihydrate Microspheres in Phosphate buffer pH 7.4 showed that Microspheres with 
high amount of carbopol were most effective in showing down the drug release 82.5% (F4), 
while the Micro spheres containing high amount of sodium alginate were released 72.1% (F6) of 
Lisinopril for 18 hrs at controlled rate. So F6 was taken as optimized formulation for its high 
entrapment efficiency and controlled release.  
                 The data obtained in the in-vitro dissolution studies were grouped in to modes of data 
treatments as follows: 
•  Cumulative percent drug release v/s time (Zero order). 
• Cumulative percent drug release v/s square root of time (Higuchi Matrix Model). 
• Log cumulative percent drug retained v/s time (first order). 
• Log cumulative percent drug release v/s log time (krosmeyer peppas model). 
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                 The results of the in vitro dissolution studies of formulations F1 to F6 are shown in 
Table No.15-20. The plots of cumulative percentage drug release v/s time, log cumulative 
percentage drug retained v/s time and cumulative percent drug release v/s square root of time, 
log cumulative percent drug release v/s log time were drawn and represented graphically. All the 
formulations exhibited anomalous (non-fickian) diffusion (n value is in between 0.5 to 1.0) 
mechanism. The drug release mechanism was diffusion controlled as the plot of higuchi model is 
linear. 
Morphological Examination 
     Morphology of the microspheres was investigated by scanning electron microscopy. 
The photographs of formulations taken by scanning electron microscope were shown in the 
Figures No.3 and 4. The microspheres were spherical in shape and free flowing. The surface of 
microspheres was observed as smooth as shown in the Figure.No.4. 
Stability Studies 
     Stability study was carried out for the formulations F1 and F5 at 37°C ± 1°C & 60° C 
for a period of 45 days and the results were noted in Table No.23. The decrease in the 
percentage yield of formulations F1 and F5 were less, after 45 days of stability studies and they 
were considered as stable products. 
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SUMMARY AND CONCLUSION 
               The study was undertaken to formulate and evaluate Lisinopril dihydrate 
microspheres using gelatin as a natural polymer and carbopol and sodium alginate in different 
proportions. Preformulation studies of Lisinopril were done initially and results directed for 
the further course of formulation. Based on the preformulation studies different batches were 
prepared using selected excipients. Prepared microspheres were evaluated for the % yield, 
drug content, Entrapment efficiency, Particle size determination, In-Vitro dissolution test and 
scanning electron microscopy, stability studies. 
 
The drug content and entrapment efficiency were good. Among all the formulations 
F6 showed better results in controlled and slow release of drug from microspheres. 
Formulations showed controlled release for 24 hrs.        
                                 
            Dissolution was carried out in phosphate buffer pH 7.4 at 258nm. All the formulations 
were evaluated using different kinetic models i.e. Zero order kinetics, first order kinetics, 
korsmeyer peppas model and Higuchi kinetics. All the formulations exhibited Non fickian 
diffusion mechanism. The drug release was diffusion controlled as the plot of Higuichi model 
was found to be linear. F6 followed Zero order kinetics model.  
 
            Surface morphology and sphericity were also good. The formulation F6 was selected 
as an optimized formulation as it has high entrapment efficiency, good flow property, high 
percentage yield and following zero order kinetics with 72.1 % of drug release in 18 hours. 
                    
            The Micro encapsulation of Lisinopril Dihydrate  with gelatin,  gelatin –carbopol and 
gelatin-Sodium alginate by co-acervation phase separation technique utilizing temperature 
change and cross linking with formaldehyde, was able to sustain the drug release efficacy. 
The microspheres having gelatine-sodium alginate and gelatin-carbopol polymers mixtures 
(F6&F3) provides the best sustained release formulations and other formulations (F1, F2) 
may be suitable for prolonged action formulations. These studies compared the release 
behaviour of gelatin, gelatin-sodium alginate and gelatin –carbopol controlled release system 
of Lisinopril microspheres. The F3 & F6 formulations had more pronounced controlled 
release effects compared with other formulations and F6 formulation is considered as 
optimised formulation among all formulations. 
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